Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Nasolacrimal Duct Obstruction, Thyroid Cancer
About this trial
This is an interventional prevention trial for Nasolacrimal Duct Obstruction focused on measuring Nasolacrimal Duct Obstruction, Artificial Tears, Thyroid Cancer
Eligibility Criteria
Inclusion Criteria: Radio-iodine therapy for thyroid cancer Radioiodine therapy ≥150 mCi Age 18 or older Exclusion Criteria: Use of eye drops, other than artificial tears History of periocular trauma with tear duct involvement/lacrimal gland trauma History of lacrimal drainage disease: canaliculitis, dacryocystitis Prior radiotherapy Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel) Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia) Nasolacrimal duct obstruction at baseline
Sites / Locations
- Vanderbilt University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Experimental Arm (Artificial Tears)
No Intervention (No Artificial Tears)
Participants in this arm will receive artificial tears to be administered in the 4 days immediately following radioactive iodine therapy. The schedule of administration will be as follows: Day 1 (day of radioactive iodine therapy): Every 15 minutes for 2 hours, then every 30 minutes for at least 4 hours or until bedtime at night Day 2: Once every 1 hour for 12 hours Day 3: Four times (approximately morning, lunch, dinner, and evening) Day 4: Two times (morning and evening)
Participants in this arm will not administer artificial tears in the 4 days immediately following radioactive iodine therapy.